Biotechnology Analyst Stringer, along with Dr. Mehta, Chief of Pain Management at NY-Presbyterian/Weill Cornell Medical Center, discuss Vertex’s VX-548 Pain Program on an Analyst/Industry conference call to be held on December 7 at 11 am.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VRTX:
- Vertex says Health Canada grants expanded use of Kalydeco
- Vertex announces EMA validation for marketing authorization of KAFTRIO
- Vertex Pharmaceuticals announces EC approval of KAFTRIO/ivacaftor combination
- Biotech Alert: Searches spiking for these stocks today
- Vertex Pharmaceuticals, Crispr Therapeutics get MHRA authorization for Casgevy